Author

Sonia S Anand

Professor, McMaster University - Cited by 90,443 - Vascular Medicine - Population Health - Gender

Biography

Dr. Sonia Anand is a professor in the Department of Medicine, and the Director of the Population Genomics Program, at McMaster. She is also a senior scientist at the Population Health Research Institute at Hamilton Health Sciences. She holds a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease. In 2010, Dr. Anand was named among the top 100 women by the Women’s Executive Network for her accomplishments in research and medicine. Her current research focuses on environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease.
Title
Cited by
Year
Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an …
M Walli-Attaei, A Rosengren, S Rangarajan, Y Breet, S Abdul-Razak, ...The Lancet 400 (10355), 811-821, 2022202
27
2022
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial
T Vanassche, P Verhamme, SS Anand, O Shestakovska, DP Leong, ...European Heart Journal-Cardiovascular Pharmacotherapy 8 (5), 462-473, 2022202
12
2022
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock, S Rangarajan, ...The Lancet Respiratory Medicine 10 (), 1169-1177, 2022202
12
2022
Use of race, ethnicity, and ancestry data in health research
C Lu, R Ahmed, A Lamri, SS AnandPLOS Global Public Health 2 (9), e0001060, 2022202
11
2022
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock, S Rangarajan, ...The Lancet Respiratory Medicine (12), 1160-1168, 2022202
10
2022
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry
KAA Fox, V Aboyans, ES Debus, U Zeymer, MR Cowie, M Patel, ...European Heart Journal-Cardiovascular Pharmacotherapy 8 (8), 825-836, 2022202
9
2022
Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of …
JW Eikelboom, J Bosch, SJ Connolly, J Tyrwitt, KAA Fox, E Muehlhofer, ...European Heart Journal-Cardiovascular Pharmacotherapy 8 (8), 78-795, 2022202
6
2022
Normal sex and age-specific parameters in a multi-ethnic population: a cardiovascular magnetic resonance study of the Canadian Alliance for Healthy Hearts and Minds cohort
JM Luu, C Gebhard, C Ramasundarahettige, D Desai, K Schulze, ...Journal of Cardiovascular Magnetic Resonance 24, 1-13, 2022202
5
2022
Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study
SS Anand, C Arnold, SI Bangdiwala, S Bolotin, D Bowdish, R Chanchlani, ...Canadian Medical Association Open Access Journal 10 (3), E599-E609, 2022202
4
2022
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD
SE Hogan, MR Nehler, S Anand, MR Patel, S Debus, MT Jackson, ...Vascular Medicine 27 (), 33-39, 2022202
4
2022
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD
MP Bonaca, M Szarek, ES Debus, MR Nehler, MR Patel, SS Anand, ...Clinical Cardiology 5 (12), 113-116, 2022202
4
2022
Comparison of investigator-reported vs centrally adjudicated major adverse cardiac events: a secondary analysis of the COMPASS trial
P Gaba, DL Bhatt, GR Dagenais, J Bosch, AP Maggioni, P Widimsky, ...JAMA network open 5 (11), e224201-e224201, 2022202
3
2022
The genetic risk of gestational diabetes in South Asian women
A Lamri, J Limbachia, KM Schulze, D Desai, B Kelly, RJ de Souza, G Paré, ...Elife 11, e81498, 0
2
2022
Changes in energy, macronutrient, and food consumption in 47 countries over the last 70 years: a systematic review and meta-analysis
C Sikorski, S Yang, R Stennett, V Miller, K Teo, SS Anand, G Paré, ...Nutrition, 111941, 0
2
2022
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits
N Govsyeyev, M Nehler, MS Conte, S Debus, J Chung, W Dorigo, I Gudz, ...Journal of Vascular Surgery 77 (4), 1107-1118. e, 030
2
2023
Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease
KG Smolderen, C Mena-Hurtado, JW Eikelboom, J Bosch, F Xie, ...European Journal of Preventive Cardiology 30 (7), 535-545, 030
2
2023
Effects of lifestyle interventions on cardiovascular risk factors in South Asians: a systematic review and meta-analysis
J Limbachia, M Ajmeri, BJ Keating, RJ de Souza, SS AnandBMJ open 2 (2), e059666, 2022202
1
2022
Microvascular disease increases the risk of lower limb amputation–A Western Danish cohort study
KKW Olesen, S Anand, T Thim, C Gyldenkerne, M MaengEuropean Journal of Clinical Investigation 52 (0), e382, 2022202
1
2022
The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial
M Qadura, MH Syed, S Anand, J Bosch, S Connolly, V Aboyans, ...Atherosclerosis 372, 4-47, 2023202
1
2023
Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort
D Wan, M Dehghan, RJ de Souza, C Ramasundarahettige, JW Eikelboom, ...European Journal of Preventive Cardiology 30 (8), 709-78, 2023202
1
2023

Referred From: https://scholar.google.com.sg/citations?hl=en&user=UHlRrBcAAAAJ

Cited by
Citations 90443
h-index 114
i10-index 346
Recommended Journals
Open Access Journals